Concord Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹326.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.39 per cent from ₹277.77 crore. This corresponds to a year-on-year *(YoY) decline of 24.15 per cent.
Operating Profit
Operating Profit stands at ₹118.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 24.57 per cent from ₹95.01 crore. This corresponds to a year-on-year *(YoY) decline of 37.34 per cent.
PBDT
PBDT stands at ₹133.62 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.37 per cent from ₹104.91 crore. This corresponds to a year-on-year *(YoY) decline of 32.57 per cent.
Profit Before Tax
Profit Before Tax stands at ₹114.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 32.40 per cent from ₹86.16 crore. This corresponds to a year-on-year *(YoY) decline of 37.85 per cent.
Net Profit
Net Profit stands at ₹88.47 crore, reflecting a quarter-on-quarter *(QoQ) increase of 39.02 per cent from ₹63.64 crore. This represents a 36.98 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Concord Biotech Ltd News
Concord Biotech Ltd Earnings
- YOY
- QOQ
Concord Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Concord Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Concord Biotech Ltd Financial Reports
Concord Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Concord Biotech | -0.78% | 1.41% | 3.41% | 24.23% | -4.37% | -26.42% |
| Alembic Pharma | 1.99% | 6.07% | 13.36% | 27.11% | -0.54% | -16.64% |
| Jubilant Pharmo | -0.66% | 1.54% | -0.24% | 13.15% | -9.61% | -19.15% |
| Alivus Life | 0.60% | 3.26% | 11.68% | 15.11% | 28.71% | 11.12% |
| Viyash Scientific | 0.41% | 9.06% | 18.06% | 50.49% | 42.26% | 56.32% |
| Corona Remedies | 2.93% | 3.73% | 20.05% | 37.66% | 39.32% | 42.17% |
| Marksans Pharma | -0.97% | 0.36% | 10.41% | 58.87% | 45.24% | 0.46% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : SUDHIR JAIRAM VAID
ED / Joint MD / CEO / Promoter : ANKUR VAID
Non Executive Director : Ravi Kapoor
Non Executive Director : Rajiv Agarwal
Independent Non Exe. Director : BHARTI KHANNA
Independent Non Exe. Director : Amitabh Thakore
Independent Non Exe. Director : Arvind Agarwal
Independent Non Exe. Director : Jayaram Easwaran
Independent Non Exe. Director : Mandayam Chakravarthy Sriraman
Company Sec. & Compli. Officer : Hina Ronak Patel